These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 15155136)

  • 41. Current and emerging strategies for the management of acute myeloid leukemia in the elderly.
    Laubach J; Rao AV
    Oncologist; 2008 Oct; 13(10):1097-108. PubMed ID: 18922830
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
    O'Farrell AM; Yuen HA; Smolich B; Hannah AL; Louie SG; Hong W; Stopeck AT; Silverman LR; Lancet JE; Karp JE; Albitar M; Cherrington JM; Giles FJ
    Leuk Res; 2004 Jul; 28(7):679-89. PubMed ID: 15158089
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biomarker targets and novel therapeutics.
    Clouser M; Hess LM; Chambers SK
    Cancer Treat Res; 2009; 149():85-105. PubMed ID: 19763432
    [No Abstract]   [Full Text] [Related]  

  • 44. The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors.
    Hunter HM; Pallis M; Seedhouse CH; Grundy M; Gray C; Russell NH
    Br J Haematol; 2004 Oct; 127(1):26-33. PubMed ID: 15384974
    [TBL] [Abstract][Full Text] [Related]  

  • 45. FLT3 inhibition in acute myeloid leukaemia.
    Knapper S
    Br J Haematol; 2007 Sep; 138(6):687-99. PubMed ID: 17655729
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia.
    Braun T; Fenaux P
    Br J Haematol; 2008 May; 141(5):576-86. PubMed ID: 18410457
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia.
    Tauro S; Craddock C; Peggs K; Begum G; Mahendra P; Cook G; Marsh J; Milligan D; Goldstone A; Hunter A; Khwaja A; Chopra R; Littlewood T; Peniket A; Parker A; Jackson G; Hale G; Cook M; Russell N; Mackinnon S
    J Clin Oncol; 2005 Dec; 23(36):9387-93. PubMed ID: 16314618
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype.
    Palmieri S; Ferrara F; Leoni F; Ciolli S; Pollio F; D'Amico MR; Celentano M; Viola A; Vicari L; Izzo B; Pane F
    Hematol Oncol; 2007 Mar; 25(1):1-5. PubMed ID: 17036374
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup.
    Schlenk RF; Benner A; Krauter J; Büchner T; Sauerland C; Ehninger G; Schaich M; Mohr B; Niederwieser D; Krahl R; Pasold R; Döhner K; Ganser A; Döhner H; Heil G
    J Clin Oncol; 2004 Sep; 22(18):3741-50. PubMed ID: 15289486
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biology and management of relapsed acute myeloid leukaemia.
    Craddock C; Tauro S; Moss P; Grimwade D
    Br J Haematol; 2005 Apr; 129(1):18-34. PubMed ID: 15801952
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Farnesyltransferase inhibitors in myelodysplastic syndrome.
    Feldman EJ
    Curr Hematol Rep; 2005 May; 4(3):186-90. PubMed ID: 15865870
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel therapeutic targets.
    Farley J; Birrer MJ
    Cancer Treat Res; 2009; 149():63-84. PubMed ID: 19763431
    [No Abstract]   [Full Text] [Related]  

  • 54. Treatment for relapsed acute myeloid leukemia: what is new?
    Ofran Y; Rowe JM
    Curr Opin Hematol; 2012 Mar; 19(2):89-94. PubMed ID: 22227525
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibitors of farnesyltransferase: a rational approach to cancer chemotherapy?
    Bell IM
    J Med Chem; 2004 Apr; 47(8):1869-78. PubMed ID: 15055985
    [No Abstract]   [Full Text] [Related]  

  • 56. New developments in the treatment of acute myeloid leukemia: focus on topotecan.
    Kantarjian H
    Semin Hematol; 1999 Oct; 36(4 Suppl 8):16-25. PubMed ID: 10622225
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The strategy for the therapy of acute myeloid leukemias in adults].
    Savchenko VG; Parovichnikova EN; Isaev VG; Kucher RA
    Ter Arkh; 1992; 64(7):4-17. PubMed ID: 1440365
    [No Abstract]   [Full Text] [Related]  

  • 58. Immunohistochemical assays of farnesyltransferase inhibition in patient samples.
    Adjei AA
    Methods Mol Med; 2003; 85():141-5. PubMed ID: 12710205
    [No Abstract]   [Full Text] [Related]  

  • 59. Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations.
    Brunner TB; Hahn SM; Gupta AK; Muschel RJ; McKenna WG; Bernhard EJ
    Cancer Res; 2003 Sep; 63(18):5656-68. PubMed ID: 14522880
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Farnesyltransferase inhibitors as anticancer agents: current status.
    Zhu K; Hamilton AD; Sebti SM
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1428-35. PubMed ID: 14763128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.